MannKind Co. (NASDAQ:MNKD – Get Free Report) insider Stuart A. Tross sold 55,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total transaction of $403,700.00. Following the transaction, the insider now directly owns 967,191 shares in the company, valued at $7,099,181.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
MannKind Stock Down 0.6 %
Shares of MNKD traded down $0.04 during mid-day trading on Friday, hitting $7.35. 4,822,462 shares of the company’s stock were exchanged, compared to its average volume of 2,065,039. The firm has a fifty day moving average of $6.52 and a two-hundred day moving average of $5.54. MannKind Co. has a twelve month low of $3.17 and a twelve month high of $7.63. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of 183.67 and a beta of 1.30.
MannKind (NASDAQ:MNKD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. MannKind had a net margin of 4.73% and a negative return on equity of 11.97%. The company had revenue of $72.39 million for the quarter, compared to analyst estimates of $64.81 million. During the same quarter in the prior year, the business posted ($0.02) EPS. MannKind’s quarterly revenue was up 48.9% on a year-over-year basis. On average, equities analysts predict that MannKind Co. will post 0.11 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of research analysts recently commented on the stock. Oppenheimer boosted their price objective on shares of MannKind from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. Leerink Partnrs raised shares of MannKind to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Leerink Partners assumed coverage on shares of MannKind in a research report on Monday, September 9th. They set an “outperform” rating and a $8.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $8.67.
Get Our Latest Stock Analysis on MNKD
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Read More
- Five stocks we like better than MannKind
- How to Use the MarketBeat Excel Dividend Calculator
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- What is a Special Dividend?
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Canada Bond Market Holiday: How to Invest and Trade
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.